Register Today for a Webinar Featuring an Opportunity to License a Polymeric Delivery Platform for Therapeutics
On Wednesday, January 27th, you are invited to a webinar featuring Dr. Stephan T. Stern of the Frederick National Laboratory for Cancer Research discussing a novel polymeric drug delivery platform that targets the lymphatic system and brain through scavenger receptor A1 (SR-A1) mediated transcytosis. The lymphatic-targeting polymeric drug delivery system is particularly well suited for delivery of immunomodulatory drugs and delivering cancer therapeutics to the lymphatic environment that metastatic cancer cells use to spread to other parts of the body, including the brain. The competitive advantages of this technology are:
• High levels of prodrug preferentially distributed to SR-A1-expressing cells, including myeloid/APC;
• Active drug is released slowly in a controlled manner, without burst release, which has not yet been achieved with current nanomedicine platforms;
• The prodrug preferentially accumulates in the lymphatic system because of SR-A1-mediated transcytosis;
• Application to a wide range of therapeutics requiring crossing the blood-brain barrier.
This event is being hosted by the NCI Technology Transfer Center’s Invention Development and Marketing Unit. It is a great opportunity to interact with the inventor, ask questions, and assess the opportunity to license or co-develop this technology.
More information on the technology can be found here.
Registration for the event and further details can be found here.